By Susan Ning Hazel Yin Ruohan Zhang King&Wood Mallesons’ International Trade Group
On May 4, 2015, the NDRC published Notice on Reinforcing Supervision over Medical Prices (“Notice”). In the Notice, the NDRC issued a range of specific opinions on the supervision over medical price, including immediately launching special inspections into illegal conducts under Pricing law and AML and some other specific issues. In this article, we would analyze the antitrust issues which may occur in such special inspections, in order to provide advice for antitrust compliance in pharmaceutical sector.
Continue Reading NDRC Targets Price-related Illegal Conducts in the Pharmaceutical Sector